Digital Biomarkers Market to Reach US$ 39.28 Billion by 2033 as Wearables, Remote Monitoring and AI-Driven Clinical Insights Gain Wider Adoption

April 13, 2026 - The global Digital Biomarkers Market is entering a strong expansion phase as healthcare and life sciences organizations increasingly turn to digitally captured physiological, behavioral and functional signals to improve diagnosis, monitoring and treatment development. According to the market data provided for this release, the Digital Biomarkers Market reached US$ 6.18 billion in 2025 and is expected to reach US$ 39.28 billion by 2033, growing at a CAGR of 22.7% during the forecast period 2026-2033.

Download This Report: https://www.datamintelligence.com/download-sample/digital-biomarkers-market?kailas

The market is gaining momentum as digital biomarkers move from a promising innovation theme into a more established commercial and clinical category. What is making the difference now is the growing ability of wearables, sensors, mobile applications and integrated analytics platforms to generate continuous, real-world health data outside traditional clinical settings. Companies such as Koneksa, Empatica, Evidation and Altoida are all positioning digital biomarkers as tools that can support more precise clinical trials, richer multimodal datasets and earlier insights into disease progression and treatment response.

The market is segmented by system component into Wearable Devices, Mobile Applications, Sensors, Digital Platforms, Data Integration & Analytics Platforms and Others. This structure reflects how digital biomarkers are increasingly being built as connected ecosystems rather than stand-alone tools. Wearables remain especially important because they generate continuous physiological and behavioral data, while analytics platforms and digital integration systems are becoming more valuable as companies seek to turn raw health signals into validated clinical insights. Koneksa, for example, describes its platform as integrating digital biomarkers, wearable sensors and traditional clinical data into unified evidence-generation workflows.

By application, the market covers Cardiovascular Diseases, Neurological Disorders, Respiratory Disorders, Metabolic Disorders, Gastrointestinal Disorders and Others. This wide disease coverage reflects one of the strongest features of the market: digital biomarkers are not being developed for just one therapeutic category. Koneksa highlights clinical-study work across neurology, oncology, respiratory, cardiovascular and infectious diseases, while Altoida is focused on neurological conditions and cognitive health through multimodal digital neuro-assessment.

By end user, the market spans Pharmaceutical Companies, Healthcare Providers, Payers, Academic & Research Institutions and Others. Pharmaceutical companies continue to play a central role because digital biomarkers are increasingly being used to improve endpoint development, patient monitoring and decentralized trial execution. At the same time, healthcare providers and research institutions are expanding the market by using these tools for patient monitoring, disease tracking and new forms of clinical evidence generation. Evidation, for instance, says its platform is trusted by millions of individuals, giving it the ability to generate real-world health data at meaningful scale.

Regionally, the market is segmented across North America, Latin America, Europe and Asia Pacific. North America continues to hold a strong position because of its concentration of digital health companies, clinical research activity and regulatory engagement around digital health technologies. Europe also remains important through clinical innovation and digital health adoption, while Asia Pacific is expected to gain relevance as connected health infrastructure, mobile healthcare use and remote-monitoring adoption expand further.

Recent company developments show how quickly the field is maturing. In June 2025, Empatica announced that the U.S. FDA had authorized its pulse oximetry algorithm with a Predetermined Change Control Plan (PCCP), which the company described as the first-ever PCCP authorization for a pulse oximetry device. Later, Empatica also announced a new FDA clearance for cardiac digital biomarkers and said that its health monitoring platform had first received FDA clearance in November 2022, with clinically validated biomarkers including electrodermal activity, SpO2, skin temperature and movement during sleep.

Product innovation is also accelerating on the device side. In June 2025, Empatica unveiled EmbraceMini, which it described as the world's smallest actigraphy wearable for clinical trials. That launch matters because miniaturization, patient comfort and study compliance are becoming more important as digital biomarkers move deeper into decentralized and longitudinal research models.

Koneksa continues to represent the clinical-trial and evidence-generation side of the market. The company says it began as a pioneer in digital biomarkers and now supports evidence generation through digital endpoints, multimodal datasets and AI-powered insights. It also states that its scaled compute has enabled 10x to 20x faster delivery of extracted insights. Earlier, Koneksa said it had built a clinical pipeline with 15 digital biomarker programs in development and more than 20 peer-reviewed papers, highlighting the scientific depth that is increasingly shaping competition in this market.

The neurological segment is also becoming more commercially visible. Altoida says its Digital NeuroMarker Platform is a 10-minute, self-administered assessment that captures hundreds of digital biomarkers across motor, speech, augmented-reality and cognitive domains. The company has also highlighted 2025 research presented at global conferences showing how multimodal digital biomarkers can support earlier and more sensitive clinical insights in Alzheimer's disease and related neurodegenerative conditions.

On the real-world data side, Evidation has continued to broaden the type of multimodal datasets available to researchers and healthcare partners. In January 2026, the company announced a temporal proteomics platform and autoimmune cohort designed to support biomarker discovery, treatment-response modeling and immune-system foundation models. In April 2026, it launched an interactive dermatology cohort and shared preliminary insights from its AI-enabled data collection platform. Evidation also recently noted that one of its senior leaders came from Our Future Health, where digital health data integration supported research involving more than one million participants, reinforcing the increasing scale at which digital biomarker ecosystems are now operating.

The competitive landscape includes Koneksa Health, Altoida Inc, Empatica Inc, Evidation Health, Inc., ActiGraph LLC, Quartet Health, IXICO plc, VivoSense, Aural Analytics, Neurotrack Technologies, Inc and others. What distinguishes this market, however, is that competition is no longer centered only on hardware or app development. It is increasingly shaped by validation, regulatory credibility, multimodal integration, disease-specific analytics and the ability to generate clinically meaningful data in real-world settings.

Purchase This Report: https://www.datamintelligence.com/buy-now-page?report=digital-biomarkers-market?kailas

Looking ahead, the Digital Biomarkers Market is expected to benefit from continued growth in remote care, decentralized trials, digital therapeutics, AI-assisted analytics and patient-centric research models. As pharmaceutical companies and healthcare providers look for better ways to capture disease signals continuously rather than episodically, digital biomarkers are becoming more commercially and clinically relevant.

With the market projected to rise from US$ 6.18 billion in 2025 to US$ 39.28 billion by 2033, digital biomarkers are increasingly being recognized as a foundational part of the future healthcare-data infrastructure. The next phase of growth is likely to be shaped not only by rising adoption, but by how effectively companies convert digital signals into validated, trusted and actionable clinical evidence.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.